Likewise, a report from EORTC gave no indication that the presence of IDH mutations predicted improved response to procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-L-nitrosourea, and vincristine (PCV) chemotherapy in WHO III anaplastic oligodendrogliomas and hypothesized that the favorable survival in IDH mutated gliomas was primarily due to a less aggressive biological behavior, rather than enhanced chemotherapeutic sensitivity [12]. The gene discussed is IDH1; the disease is anaplastic oligodendroglioma.